Prior authorization required for listed SADs

Prior authorization is required when a provider requests healthcare-professional administration of any medication listed in Table 1; approvals for provider administration are for an initial monitored transition period (typically 60 days, or 90 days for specified drugs such as Xolair®).

• Authorization approval authorizes provider administration for the initial monitoring/transition period only (standard = 60 days; Xolair example = 90 days).

Table 1 entries subject to Pharmacy Prior Authorization ORPTCOTH042

Medications shown in Table 1 are governed by the Pharmacy Prior Authorization Policy ORPTCOTH042; Table 1 entries indicate the HCPCS code, brand/generic name, whether a medical-benefit transition is available, and whether the product is pharmacy-benefit-only.

• If 'Pharmacy Benefit Only' is marked in Table 1 the medication will always start under the pharmacy benefit and is not eligible for SAD policy exception requests.

Use listed HCPCS/J/Q mappings from Table 1 when submitting claims/requests

Use the HCPCS, J, and Q/C code mappings listed in Table 1 when submitting prior authorization requests or claims for provider administration of SADs; specific codes in the table map to brand and generic drug names and flags.

• Examples: J3590 → multiple listed brands (e.g., Enspryng, Cosentyx); J3490 → Ozempic/Wegovy/Mounjaro; Q5135* and other Q/C codes map to Ustekinumab biosimilars.
• Follow the exact HCPCS/J/Q/C code listed in Table 1 for the product being requested.

New or off‑label indication requests require New Drug/Indication review

Requests for indications approved by the FDA within the previous six months, or for non‑FDA (off‑label) indications, must be reviewed under the New Drug/Indication awaiting P&T procedures and require supporting references and prescriber rationale.

• New FDA indications (≤6 months) are reviewed using the New Drug and/or Indication Awaiting P&T Review (ORPTCOPS047).
• Off‑label indications must be listed in AHFS, Drugdex, or NCCN and be supported by the prescriber's medical rationale and evidence.

Initiate certain SADs under the medical benefit for 60–90 day monitoring

Some medications listed in Table 1 that are marked 'Medical Transition Available' must be initiated under the medical benefit for a defined monitoring/training period (typically 60 days; certain products such as Xolair® require 90 days).

• Continuation of provider administration after the transition period remains subject to the medical necessity criteria in this policy.

Provide chart notes documenting medical rationale for provider administration

Include relevant chart notes documenting the medical rationale for provider administration; documentation must support one of the policy criteria (e.g., recent anaphylaxis requiring epinephrine or hospitalization, allergic reaction to the requested medication, inability to safely self-administer due to cognitive or physical impairment, inability to recognize or act on anaphylaxis, or diagnosed needle phobia).

• Chart documentation must explicitly support the chosen rationale and timeframe (e.g., history of anaphylaxis within past 5 years).

Include package inserts and external references to support requests

Use the policy's referenced supporting resources to substantiate medical necessity determinations; the document specifically cites relevant package inserts, the Noridian SADs policy, and the CMS Medicare Benefit Policy Manual.

• Referenced resources: package inserts; Noridian Self‑Administered Drugs policy; CMS Medicare Benefit Policy Manual Chapter 15.

Consult Table 1 for medications, codes, and benefit flags

Refer to Table 1 for the complete list of medications covered under the Miscellaneous Products SAD scope and to determine the HCPCS mapping, Medical Transition Available flag, and Pharmacy Benefit Only flag for each product.

• Table 1 identifies whether a medication is eligible for medical-benefit transition or is Pharmacy Benefit Only.

Billed J/Q codes with multiple routes must include JA or JB modifier or claim will be denied

Claims for drugs marked with an asterisk (*) in Table 1 that have multiple routes must be billed with the required route modifier (JA for intravenous or JB for subcutaneous); claims submitted without the appropriate JA/JB modifier will be denied.

• JA = Intravenous administration; JB = Subcutaneous administration.
• Subcutaneously administered drugs listed as Usually Self‑Administered will be denied as a benefit exclusion absent meeting medical necessity criteria.

Provider administration requests for self‑administered products are reviewed for medical necessity; pharmacy‑only items are ineligible

Requests for healthcare (provider) administration of medications labeled for patient self‑administration are subject to medical necessity review; medications that are Pharmacy Benefit Only will not be eligible for SAD policy exceptions and will start under the pharmacy benefit.

• Any medication labeled for patient self‑administration in Table 1 may be reviewed for medical necessity if provider administration is requested.
• Pharmacy‑benefit‑only products are not eligible for exception to start under medical benefit.

Follow Table 1, coding, prior authorization and documentation requirements (no other explicit actions listed)

No additional explicit authorization actions or alternate denial procedures are specified beyond those in Table 1 and the policy language; follow Table 1 mappings, prior authorization requirements, modifier rules, and documentation guidance as stated.

• Table 1 and policy sections provide the actionable requirements for authorization, coding, and documentation.

Cover initial 60 days (or manufacturer period) at provider office for initiation

The first 60 days (or manufacturer‑specified period) of therapy for SADs must be covered at a provider's office to allow monitoring, patient training in administration technique, and recognition of anaphylaxis; extended monitoring beyond 60 days is permitted when recommended by the manufacturer (example: Xolair® = 90 days).

• This office‑based initiation requirement applies upon initiation or approval for a SAD listed drug.

Initial provider administration may occur in infusion center, office, or home for flagged drugs

Some medications flagged in Table 1 as having a medical transition available require initial provider administration (medical benefit) in settings such as infusion center, office, or home to permit monitoring and patient training; products marked 'Pharmacy Benefit Only' are initiated via pharmacy and are not eligible for these SAD exceptions.

• Settings for initial administration include infusion center, office, or home per the product's transition designation.

HCPCS/Q/C code mappings provided for ustekinumab products (no interchange preference stated)

Ustekinumab and its biosimilars are mapped to various Q/C/HCPCS codes in Table 1; the policy provides the code mappings but does not state a biosimilar preference or interchange rule.

• Multiple Q and HCPCS codes (for example Q5100, Q5098, Q5099*, Q9996, J3357) are mapped to branded and biosimilar ustekinumab products in Table 1.

Coding-related denial risk: missing JA/JB modifiers

Repeat: claims for Table 1 drugs marked with an asterisk billed without JA/JB modifiers may be denied; ensure the correct route modifier is applied for J/Q codes with multiple routes of administration.

• Missing or incorrect modifiers on J/Q codes is a common cause for claim denials under this policy.